Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MpoxVax AFRIVAC

Financiado

Cerrado

Expanding a prospective clinical trial examining the immune response of partici...

Expanding a prospective clinical trial examining the immune response of participants receiving Modified Vaccinia Ankara vaccine to Africa. The current Mpox outbreak affecting the Democratic Republic of the Congo, ongoing since 2023, has resulted in more than 19,000 causes and over 1,000 deaths, with women accounting for more than half of those affected. The previous... ver más

31/03/2027

Líder desconocido

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-03

HORIZON-JU-GH-EDCTP3-2024-Mpox: Mobilisation of Emergency funding f... Expected Outcome:This topic aims at supporting activities that contribute to answering the most pres...

I+D

Cerrada hace 10 meses

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

UNIVERSITE CATHOLIQUE DE BUK...

THE UNIVERSITY COURT OF THE...

UGANDA NATIONAL HEALTH RESEA...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 29 meses Fecha Inicio: 2024-10-03
Fecha Fin: 2027-03-31

Líder del proyecto Líder desconocido

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The current Mpox outbreak affecting the Democratic Republic of the Congo, ongoing since 2023, has resulted in more than 19,000 causes and over 1,000 deaths, with women accounting for more than half of those affected. The previous global Mpox outbreak in 2022 was alleviated in part with use of preventive vaccination using modified vaccina Ankara (MVA) vaccine. However, whether this vaccine induces sufficient immune responses in women and those with immunosuppression, which is common in affected areas, and how long vaccine-induced immunity lasts is not well defined. Furthermore, outbreak responses within Africa are also limited by lack of robust diagnostics. The Mpox AFRIVAC Project will engage with key stakeholders and the community to address these knowledge gaps and capacity limitations by adapting a phase 4 clinical trial of pre-exposure vaccination against Mpox currently underway in Europe to African sites affected by the current outbreak. This will be accompanied by technology transfer to develop Mpox immune diagnostics and knowledge transfer to develop a regional vaccinee-focused Clinical Trials Unit. Together, these activities will address key strategic priorities within the region, address knowledge gaps and significantly contribute to regional capacity and public health response to bring an end to the Mpox outbreak.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores